2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights
Mostafa M. Elbadawi, Wagdy M. Eldehna, Amer Ali Abd El‐Hafeez, Warda R. Somaa, Amgad Albohy, Sara T. Al‐Rashood, Keli Agama, Eslam B. Elkaeed, Pradipta Ghosh, Yves Pommier, Manabu Abe
Abstract
s = 22.68, 14.25, 18.36, 17.36, and 15.36 nM, respectively). Finally, molecular modelling was employed to justify the promising EGFR/FAK inhibition. The study outcomes afforded the first reported quinolines with potent EGFR/FAK dual inhibition.
Topics & Concepts
ChemistryEGFR inhibitorsInhibitory postsynaptic potentialKinaseGrowth inhibitionCancer researchPharmacologyEpidermal growth factor receptorBiochemistryCell growthMedicineReceptorInternal medicineCancer therapeutics and mechanismsSynthesis and biological activityQuinazolinone synthesis and applications